Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.57 |
| ▸ | IDH2 | P48735 | 3/20 | 0.57 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808227 | 0.92 | IDH1 (0.51) | IDH1IDH2MALT1HDAC8SYK | |
| SCHEMBL2243533 | 0.89 | MAPK1 (0.55) | IDH1IDH2HDAC8SYKHRH4 | |
| Hydrochloric Acid SCHEMBL3775270 | 0.88 | MAPK1 (0.53) | IDH1IDH2HDAC8SYKHRH4 | |
| SCHEMBL12526259 | 0.84 | IDH2 (0.50) | IDH1IDH2HDAC8SYKHRH4 | |
| SCHEMBL84117 | 0.83 | SYK (0.48) | IDH1IDH2MALT1SYKKDM4E | |
| SCHEMBL18657578 | 0.79 | ACHE (0.65) | IDH1IDH2SYKKDM4E | |
| Hydrochloric Acid SCHEMBL6459847 | 0.78 | MCHR1 (0.59) | HDAC8 | |
| Hydrochloric Acid SCHEMBL6459856 | 0.78 | MCHR1 (0.59) | HDAC8 | |
| SCHEMBL3775324 | 0.77 | IDH1 (0.60) | IDH1IDH2HDAC8SYK | |
| SCHEMBL14834214 | 0.76 | HSD11B1 (0.51) | IDH1IDH2HDAC8PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | IDH1 3637/4885IDH2 2949/4885MALT1 3688/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | IDH1 3637/4885IDH2 2949/4885MALT1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.